Evaluation of Surfactant Protein B in the Differential Diagnostics of Dyspnea

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

55 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-10-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Establishing new biochemical markers in the differential diagnostics and risk stratification in heterogeneous patient collectives is becoming more and more important. The markers should be objective, reliable, reproducible, quick and cost effective as well as specific and sensitive. Concerning the differential diagnostics of "dyspnea", NT-pro-BNP plays the most important role for the evaluation of a cardiac origin. However, a corresponding biochemical marker for pulmonary stress is lacking. The aim of the study at hand therefore was the evaluation of surfactant protein B in the differential diagnostics of pulmonary and cardiac diseases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diagnostic and Prognostic Value of New Biomarkers in Patients With Heart Disease

NCT01374880

Heart Failure Dyspnea Pulmonary Disease

UNKNOWN

Diaphragmatic Function as a Biomarker

NCT05903001

Dyspnea; Asthmatic COPD Fibrosis +3 more

RECRUITING

Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia

NCT03473119

Pneumonia Chronic Obstructive Pulmonary Disease Asthma

UNKNOWN

Using NT-proBNP to Detect Chronic Heart Failure in Patients With Chronic Obstructive Pulmonary Disease

NCT01801722

Chronic Obstructive Pulmonary Disease Chronic Heart Failure

COMPLETED

Serum Surfactant Protein-D as Predictor of Disease Severity in Hospitalized COPD Patients

NCT07154953

COPD

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyspnea Cardiac Disease Pulmonary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients presenting with dyspnea and giving informed consent

Exclusion Criteria

* outpatients
* lack or doubt of legal competence
* indication for mechanical ventilation
* pregnancy
* palliative patients
* CPAP/LTOT
* BMI \> 30 kg/m2
* sepsis
* anemia
* dialysis

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No